Biocon Biologics has partnered with Sandoz to exclusively market Adalimumab BS for subcutaneous injection, indicated for immune-related diseases, in Japan.
New Delhi, Dec 22 (PTI) Biocon Biologics on Friday said it has given exclusive rights to sell and distribute a drug, indicated for the treatment of immune-related diseases, in Japan.
The company has signed a distribution agreement with Sandoz, granting the company the exclusive rights to promote, sell and distribute Adalimumab BS for subcutaneous injection in Japan, Biocon Biologics said in a statement.
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Biocon Biologics is a subsidiary of Bengaluru-headquartered Biocon Ltd.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback